Clearside Biomedical (CLSD) Reports In-Line Q3 EPS

Clearside Biomedical (NASDAQ: CLSD) reported Q3 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $410 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance
• Ollie's Bargain Outlet (OLLI) Tops Q2 EPS by 28c, Offers Guidance